Transcriptome Analysis Reveals Mitochondrial Gene Signature Upregulation In Gastric Cancers Expressing The Stem Cell Marker Cd133

Gastric cancers expressing the stem cell marker CD133 are more aggressive than those that do not express the marker, and are associated with more unfavorable clinical outcomes. The CD133-associated aggressive behavior of gastric cancer remains poorly understood at the molecular level. In the present study, we performed gene expression profiling of bead-sorted CD133+ and CD133- KATO III cell lines to derive in vitro molecular signatures of CD133 expression in gastric cancer. Three expression signatures associated with CD133 expression (9Mitochondria9, 9Cell cycle9, and 9Lipid metabolism9) were inferred upon study of a module association map of the key molecular signatures associated with CD133 expression in gastric cancer. Using the public gene expression profiles, we show that the patients with overexpression of CD133 show unfavorable clinical outcomes compared to CD133- patients in the context of up-regulation of 9Mitochondria9 expression signature. We further showed that CD133+ KATO III cells had a higher mitochondrial function and were more susceptible to the mitochondrial inhibitors rotenone, antimycin A, and NaN 3 , than were CD133- cells. Together, our findings suggest that transcriptional up-regulation of the 9Mitochondria9 gene signature may identify CD133+ gastric cancers; such data are of clinical and pharmacological relevance. Note: This abstract was not presented at the meeting. Citation Format: Han Hong Lee, Yoon Ho Ko, Tae-Min Kim, Won-Sang Park. Transcriptome analysis reveals mitochondrial gene signature upregulation in gastric cancers expressing the stem cell marker CD133 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3883. doi:10.1158/1538-7445.AM2017-3883